| Title： | Expert consensus on the testing process, reporting template and clinical application of PAX1 and JAM3 dual gene methylation detection in cervical cancer |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis |
| Countries and regions： | China |
| Guidelines users： | Clinicians, hospitals, and related units are responsible for the inspectors who perform methylation detection technology |
| Evidence classification method： | Centre for Evidence-Based Medicine Levels of Evidence |
| Development unit： | Chinese Association of Integrative Medicine；Chinese Society of Laboratory Medicine；Chinese Laboratory Physician Branch of Chinese Medical Doctor Association；China Maternal and Child Health Association；China International Exchange and Promotive Association for Medical and Health Care |
| Registration time: | 2024-10-08 |
| Registration number： | PREPARE-2024CN740 |
| Purpose of the guideline: | Cervical cancer is a common genital malignant tumor that seriously threatens women's health worldwide and has become a major public health problem worldwide. Methylation detection has been recognized as a new detection method for cervical cancer by the WHO and multinational cervical cancer screening guidelines, but it is necessary to accumulate large-sample prospective research data as a guideline basis. This expert consensus will be revised in a timely manner according to the progress of clinical research, and provide testers and doctors with guidance on the detection process, report template and clinical application of PAX1 and JAM3 dual gene methylation markers, so as to promote the clinical standardized application of cervical cancer methylation detection to meet the needs of clinical application. In order to further improve the cervical cancer prevention and treatment service system, strive to curb the rising trend of cervical cancer incidence and mortality, reduce the burden of cervical cancer disease, further improve the cervical cancer prevention and treatment service system, improve the comprehensive prevention and treatment capacity, and accelerate the elimination process of cervical cancer in China. |
